Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model

Fundamental and Clinical Pharmacology

Volumn 27, Issue 4, 2013, Pages 364-372

  Kharin, Sergey ^a,b   Krandycheva, Valeria ^a,b   Tsvetkova, Alena ^a,b   Strelkova, Marina ^a   Shmakov, Dmitry ^a  

^a INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^b KIROV STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cardiotoxicity; Doxorubicin; Heart; Rat model; Repolarization

Indexed keywords

DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DISPERSION; ELECTROCARDIOGRAPHY; EPICARDIUM; EPICARDIUM MAPPING; FEMALE; HEART LEFT VENTRICLE; HEART REPOLARIZATION; HEART RIGHT VENTRICLE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RAT; SINUS RHYTHM; T WAVE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART DISEASES; HEART VENTRICLES; PERICARDIUM; RATS; VENTRICULAR FUNCTION; VENTRICULAR REMODELING;

EID: 84879549635     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01037.x     Document Type: Article

References (56)

1. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N.Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell. Biochem. (2000) 207 77-85.
2. Chen B., Peng X., Pentassuglia L., Lim C.C., Sawyer D.B.Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol. (2007) 7 114-121.
3. Šimůnek T., Štěrba M., Popelová O., Adamcová M., Hrdina R., Geršl V.Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. (2009) 61 154-171.
4. Tong J., Ganguly P.K., Singal P.K.Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol. (1991) 260 H909-H916.
5. Siveski-Iliskovic N., Kaul N., Singal P.K.Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation (1994) 89 2829-2835.
6. Kazachenko A.A., Okovityǐ S.V., Kulikov A.N. et al.Comparative characteristics of some pharmacological models of chronic heart failure. Eksp. Klin. Farmakol. (2008) 71 16-19 (Russian).
7. Migrino R.Q., Aggarwal D., Konorev E., Brahmbhatt T., Bright M., Kalyanaraman B.Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med. Biol. (2008) 34 208-214.
8. Cirillo R., Sacco G., Venturella S., Brightwell J., Giachetti A., Manzini S.Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J. Cardiovasc. Pharmacol. (2000) 35 100-108.
9. Thomas L., Bellmont S., Christen M.O., La Roche B., Monassier L.Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam. Clin. Pharmacol. (2004) 18 649-655.
10. Piegari E., Di Salvo G., Castaldi B. et al.Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model. Ultrasound Med. Biol. (2008) 34 370-378.
11. Xu M., Sheng L., Zhu X., Zeng S., Chi D., Zhang G.J.Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats. Tumori. (2010) 96 460-464.
12. Jensen R.A., Acton E.M., Peters J.H.Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Cancer Res. (1984) 44 4030-4039.
13. Jensen R.A., Acton E.M., Peters J.H.Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J. Cardiovasc. Pharmacol. (1984) 6 186-200.
14. van Acker S.A., Kramer K., Voest E.E. et al.Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother. Pharmacol. (1996) 38 95-101.
15. Agen C., Bernardini N., Danesi R., Della Torre P., Costa M., Del Tacca M.Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemother. Pharmacol. (1992) 30 95-99.
16. Earm Y.E., Ho W.K., So I.Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. J. Mol. Cell. Cardiol. (1994) 26 163-172.
17. Wang Y.X., Korth M.Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ. Res. (1995) 76 645-653.
18. Ducroq J., Moha Ou Maati H., Guilbot S. et al.Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). Br. J. Pharmacol. (2010) 159 93-101.
19. Doherty J.D., Cobbe S.M.Electrophysiological changes in animal model of chronic cardiac failure. Cardiovasc. Res. (1990) 24 309-316.
20. Shenasa H., Calderone A., Vermeulen M. et al.Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovasc. Res. (1990) 24 591-604.
21. Dhein S., Garbade J., Rouabah D. et al.Effects of autologous bone marrow stem cell transplantation on beta-adrenoceptor density and electrical activation pattern in a rabbit model of non-ischemic heart failure. J. Cardiothorac. Surg. (2006) 1 17.
22. Millar C.K., Kralios F.A., Lux R.L.Correlation between refractory periods and activation-recovery intervals from electrograms: effects of rate and adrenergic interventions. Circulation (1985) 72 1372-1379.
23. Coronel R., de Bakker J.M., Wilms-Schopman F.J. et al.Monophasic action potentials and activation recovery intervals as measures of ventricular action potential duration: experimental evidence to resolve some controversies. Heart Rhythm (2006) 3 1043-1050.
24. Hayes E., Pugsley M.K., Penz W.P., Adaikan G., Walker M.J.Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates. J. Pharmacol. Toxicol. Methods (1994) 32 201-207.
25. Varró A., Lathrop D.A., Hester S.B., Nánási P.P., Papp J.G.Ionic currents and action potentials in rabbit, rat, and guinea pig ventricular myocytes. Basic Res. Cardiol. (1993) 88 93-102.
26. Casis O., Iriarte M., Gallego M., Sánchez-Chapula J.A.Differences in regional distribution of K+ current densities in rat ventricle. Life Sci. (1998) 63 391-400.
27. Himmel H.M., Wettwer E., Li Q., Ravens U.Four different components contribute to outward current in rat ventricular myocytes. Am. J. Physiol. (1999) 277 H107-H118.
28. Nerbonne J.M., Kass R.S.Molecular physiology of cardiac repolarization. Physiol. Rev. (2005) 85 1205-1253.
29. Tomaselli G.F., Marbán E.Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc. Res. (1999) 42 270-283.
30. L'Ecuyer T., Sanjeev S., Thomas R. et al.DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. (2006) 291 H1273-H1280.
31. Ito H., Miller S.C., Billingham M.E. et al.Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. USA. (1990) 87 4275-4279.
32. Venditti P., Balestrieri M., De Leo T., Di Meo S.Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc. Res. (1998) 38 695-702.
33. Wasson S., Reddy H.K., Dohrmann M.L.Current perspectives of electrical remodeling and its therapeutic implications. J. Cardiovasc. Pharmacol. Ther. (2004) 9 129-144.
34. Kenk M., Thackeray J.T., Thorn S.L. et al.Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J.Nucl. Cardiol. (2010) 17 254-263.
35. Scamps F.Characterization of a beta-adrenergically inhibited K+ current in rat cardiac ventricular cells. J. Physiol. (1996) 491 81-97.
36. Koumi S., Wasserstrom J.A., Ten Eick R.E.Beta-adrenergic and cholinergic modulation of the inwardly rectifying K+ current in guinea-pig ventricular myocytes. J. Physiol. (1995) 486 647-659.
37. Cheng J., Niwa R., Kamiya K., Toyama J., Kodama I.Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Eur. J. Pharmacol. (1999) 376 189-201.
38. Clark R.B., Bouchard R.A., Salinas-Stefanon E., Sanchez-Chapula J., Giles W.R.Heterogeneity of action potential waveforms and potassium currents in rat ventricle. Cardiovasc. Res. (1993) 27 1795-1799.
39. Aimond F., Alvarez J.L., Rauzier J.M., Lorente P., Vassort G.Ionic basis of ventricular arrhythmias in remodeled rat heart during long-term myocardial infarction. Cardiovasc. Res. (1999) 42 402-415.
40. Bryant S.M., Shipsey S.J., Hart G.Normal regional distribution of membrane current density in rat left ventricle is altered in catecholamine-induced hypertrophy. Cardiovasc. Res. (1999) 42 391-401.
41. Volk T., Nguyen T.H., Schultz J.H., Faulhaber J., Ehmke H.Regional alterations of repolarizing K+ currents among the left ventricular free wall of rats with ascending aortic stenosis. J. Physiol. (2001) 530 443-455.
42. Berdichevski A., Meiry G., Milman F. et al.TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements. J. Pharmacol. Exp. Ther. (2010) 332 413-420.
43. Hazari M.S., Haykal-Coates N., Winsett D.W., Costa D.L., Farraj A.K.Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Toxicol. Sci. (2009) 110 224-234.
44. Kilickap S., Barista I., Akgul E., Aytemir K., Aksoy S., Tekuzman G.Early and late arrhythmogenic effects of doxorubicin. South. Med. J. (2007) 100 262-265.
45. Nousiainen T., Vanninen E., Rantala A., Jantunen E., Hartikainen J.QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J. Intern. Med. (1999) 245 359-364.
46. Galetta F., Franzoni F., Cervetti G. et al.Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed. Pharmacother. (2005) 59 541-544.
47. Hayward R., Hydock D.S.Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J. Am. Assoc. Lab. Anim. Sci. (2007) 46 20-32.
48. James A.F., Choisy S.C., Hancox J.C.Recent advances in understanding sex differences in cardiac repolarization. Prog. Biophys. Mol. Biol. (2007) 94 265-319.
49. Sampson K.J., Henriquez C.S.Electrotonic influences on action potential duration dispersion in small hearts: a simulation study. Am. J. Physiol. Heart Circ. Physiol. (2005) 289 H350-H360.
50. Vermeulen J.T., McGuire M.A., Opthof T. et al.Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc. Res. (1994) 28 1547-1554.
51. Ewer M.S., Ewer S.M.Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. (2010) 7 564-575.
52. Chauhan V.S., Downar E., Nanthakumar K. et al.Increased ventricular repolarization heterogeneity in patients with ventricular arrhythmia vulnerability and cardiomyopathy: a human in vivo study. Am. J. Physiol. Heart Circ. Physiol. (2006) 290 H79-H86.
53. Akar F.G.Left ventricular repolarization heterogeneity as an arrhythmic substrate in heart failure. Minerva Cardioangiol. (2010) 58 205-212.
54. Ajijola O.A., Nandigam K.V., Chabner B.A. et al.Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy. Am. J. Cardiol. (2008) 101 1371-1372.
55. Tsvetkova A.S., Kibler N.A., Nuzhny V.P., Shmakov D.N., Azarov J.E.Acute effects of pacing site on repolarization and haemodynamics of the canine ventricles. Europace (2011) 13 889-896.
56. Arbel Y., Swartzon M., Justo D.QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs (2007) 18 493-498.